BeiGene Completes $750 Million Secondary Offering

BeiGene, a Beijing innovative cancer biotech, raised a spectacular $750 million in a secondary offering of its shares. The price of the shares ended the session 13% higher after the funding was announced, closing the day at $115.56. BeiGene now has a market capitalization of $4.8 billion -- before the new shares are issued. In 2016, BeiGene staged a $158 million IPO on the Nasdaq exchange, pricing at $24 per share. To date, the company has raised almost $1 billion, including the IPO, a $200 million secondary offering, and Celgene's $236 million payment plus $150 investment in BeiGene shares for ex-China rights to BeiGene's PD-1 candidate. More details.... Stock Symbols: (NSDQ: BGNE) (NSDQ: CELG) Share this with colleagues: // //